| scholarly article | Q13442814 |
| P2093 | author name string | H L McLeod | |
| J Verweij | |||
| A Sparreboom | |||
| R H Mathijssen | |||
| S Marsh | |||
| L E Friberg | |||
| F A de Jong | |||
| D L Kroetz | |||
| T J Scott-Horton | |||
| P2860 | cites work | Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? | Q24670527 |
| Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects | Q28206464 | ||
| Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan | Q28249001 | ||
| Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II | Q28258225 | ||
| The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer | Q60697890 | ||
| Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion | Q67854378 | ||
| Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin | Q73330191 | ||
| Comprehensive UGT1A1 genotyping in a Japanese population by pyrosequencing | Q73552678 | ||
| Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats | Q77323126 | ||
| Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus | Q77920429 | ||
| Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity | Q80077331 | ||
| Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5'-untranslated region and exon 28. | Q31043181 | ||
| Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I | Q31145683 | ||
| Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. | Q31856730 | ||
| Modulation of irinotecan metabolism by ketoconazole | Q33183940 | ||
| Effects of St. John's wort on irinotecan metabolism | Q33184162 | ||
| Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor | Q33201555 | ||
| Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability | Q33204210 | ||
| ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition | Q33206580 | ||
| Role of pharmacogenetics in irinotecan therapy | Q33229180 | ||
| Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study | Q33256265 | ||
| Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain | Q33257334 | ||
| Molecular genetic basis of Gilbert's syndrome | Q33756586 | ||
| The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome | Q34057969 | ||
| Phase II study of activated charcoal to prevent irinotecan-induced diarrhea | Q34363207 | ||
| Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome | Q34374626 | ||
| Pharmacogenomics: road to anticancer therapeutics nirvana? | Q35551155 | ||
| Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer | Q35826887 | ||
| Pharmacogenetics of irinotecan toxicity | Q35911147 | ||
| Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea | Q36026126 | ||
| Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport | Q36265658 | ||
| CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein | Q36295072 | ||
| Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response | Q36353020 | ||
| Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations | Q36407286 | ||
| Adjuvant therapy in colon cancer--what, when and how? | Q36416697 | ||
| Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. | Q40435926 | ||
| Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. | Q40725123 | ||
| Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials | Q40995855 | ||
| Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein | Q41006727 | ||
| Caution on pedigree haplotype inference with software that assumes linkage equilibrium | Q43202210 | ||
| Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis | Q44083716 | ||
| Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea | Q44139040 | ||
| Irinotecan pharmacogenetics: is it time to intervene? | Q44790651 | ||
| Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity | Q44904891 | ||
| Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. | Q44923699 | ||
| Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes | Q45137094 | ||
| Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo | Q46616435 | ||
| Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes | Q46967012 | ||
| Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. | Q52507148 | ||
| Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. | Q55026118 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diarrhea | Q40878 |
| P304 | page(s) | 42-49 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein | |
| P478 | volume | 81 |
| Q28943493 | A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer |
| Q37050337 | A perspective on efflux transport proteins in the liver |
| Q51891830 | ABCC2 haplotype is not associated with drug-resistant epilepsy. |
| Q48881091 | ABCC2 rs2273697 and rs3740066 polymorphisms and resistance to antiepileptic drugs in Asia Pacific epilepsy cohorts. |
| Q28542007 | Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect |
| Q43254389 | Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy |
| Q36352809 | Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy |
| Q30318822 | Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management |
| Q51016323 | Circadian Clock Is Involved in Regulation of Hepatobiliary Transport Mediated by Multidrug Resistance-Associated Protein 2. |
| Q36051757 | Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo |
| Q24651239 | Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics |
| Q35946876 | Contribution of tumoral and host solute carriers to clinical drug response |
| Q44351944 | Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer |
| Q37834445 | Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma? |
| Q35902300 | Effect of ABCC2 (MRP2) transport function on erythromycin metabolism |
| Q36684423 | Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples |
| Q51579192 | Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats. |
| Q58604572 | Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy |
| Q36043023 | Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis. |
| Q38706504 | Exploring the Carbamazepine Interaction with Human Pregnane X Receptor and Effect on ABCC2 Using in Vitro and in Silico Approach. |
| Q26851060 | FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy |
| Q36806579 | Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2). |
| Q39337368 | Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression. |
| Q36943992 | GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. |
| Q37481450 | Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs |
| Q36775605 | Impact of pharmacogenomics on clinical practice in oncology |
| Q52362144 | Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. |
| Q52431756 | Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective from the International Transporter Consortium. |
| Q28287024 | Irinotecan pharmacogenomics |
| Q26775949 | Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer |
| Q46960024 | Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature |
| Q36788481 | Molecular markers of chemotherapeutic response and toxicity in colorectal cancer |
| Q38027568 | Personalized medicine policy challenges: measuring clinical utility at point of care |
| Q37182212 | PhRMA white paper on ADME pharmacogenomics. |
| Q36182023 | Pharmacogenetic pathway analysis of docetaxel elimination. |
| Q37173199 | Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? |
| Q35030489 | Pharmacogenetics and pharmacogenomics of anticancer agents. |
| Q37880875 | Pharmacogenetics of drug transporters in the enterohepatic circulation |
| Q38933314 | Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review. |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q28068930 | Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use |
| Q46504849 | Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers |
| Q36885663 | Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel |
| Q28535089 | Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan |
| Q39906223 | Posttranslational regulation of Abcc2 expression by SUMOylation system. |
| Q46164559 | Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage |
| Q43272335 | Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms |
| Q36281662 | Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis |
| Q39140289 | Renal Drug Transporters and Drug Interactions |
| Q33320638 | Renal function as a predictor of irinotecan-induced neutropenia. |
| Q53749471 | Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro. |
| Q46578287 | Role of enterohepatic recirculation in drug disposition: cooperation and complications |
| Q47107453 | Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity |
| Q43288450 | Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression |
| Q27021716 | Systemic therapies for pancreatic cancer--the role of pharmacogenetics |
| Q37587940 | The effects of ABCC2 G1249A polymorphism on the risk of resistance to antiepileptic drugs: a meta-analysis of the literature |
| Q34071782 | The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. |
| Q37537018 | The role of transporters in the pharmacokinetics of orally administered drugs |
| Q37734911 | Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. |
| Q46636676 | Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere |
| Q46038296 | UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. |
| Q34984788 | UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients |
| Q35008045 | Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy |
| Q34065294 | Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance |
| Q34897941 | Urinary elimination of coproporphyrins is dependent on ABCC2 polymorphisms and represents a potential biomarker of MRP2 activity in humans |
Search more.